Overview

This greatly expanded third edition provides a comprehensive overview of clinical psychopharmacology, incorporating the major advances in the field since the previous edition's publication. Renowned experts from psychiatry, pharmacy, and nursing have integrated basic science, psychopharmacology, and clinical practice throughout the book in order to provide a thorough basis for prescribing. It covers all key psychiatric drugs and disorders and includes the latest data on efficacy, safety and tolerability. Adopting a pragmatic approach to drug nomenclature, both Neuroscience-based Nomenclature (NbN) and older generic terminology are included in the text reflecting that clinicians are likely to use both systems. Many chapters refer to current National Institute of Health and Care Excellence (NICE) guidelines, making this a crucial resource. Edited by leading authorities in the field, Professor Peter M. Haddad and Professor David J. Nutt, Seminars in Clinical Psychopharmacology emphasises evidence-based prescribing with the aim of achieving better clinical outcomes for patients.

Full Product Details

Author:   Peter M. Haddad ,  David J. Nutt
Publisher:   RCPsych/Cambridge University Press
Imprint:   RCPsych/Cambridge University Press
Edition:   3rd Revised edition
Dimensions:   Width: 15.80cm , Height: 3.30cm , Length: 23.30cm
Weight:   1.150kg
ISBN:  

9781911623458

ISBN 10:   1911623451
Pages:   690
Publication Date:   18 June 2020
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Paperback
Publisher's Status:   Active
Availability:   In stock  
We have confirmation that this item is in stock with the supplier. It will be ordered in for you and dispatched immediately.

Table of Contents

List of contributors; Foreword Peter Tyrer; Preface; Editor's note on nomenclature; Neuroscience-based nomenclature glossary; List of abbreviations; Part I. Basic Science and General Principles: 1. A brief history of psychopharmacology Peter M. Haddad, David J. Nutt and Richard Green; 2. Psychiatric drug discovery and development Mohammed Shahid, Joanna C. Neill and John Hutchison; 3. Neurotransmission and mechanisms of drug action Brian E. Leonard; 4. Pharmacodynamics and pharmacokinetics Stuart Gill-Banham and David Taylor; 5. Pharmacogenomics and psychopharmacology Diego L. Lapetina, Esther H. Yang, Beatriz C. Henriques and Katherine J. Aitchison; 6. Good clinical practice in psychopharmacology Peter M. Haddad and Thomas R. E. Barnes; Part II. Psychopharmacology of the Main Psychotropic Drug Groups: 7. Drugs to treat depression Patrick McLaughlin and Anthony Cleare; 8. Drugs to treat anxiety and insomnia David S. Baldwin and Nathan Huneke; 9. Drugs to treat schizophrenia and psychosis (dopamine antagonists and partial agonists other than clozapine) Robert McCutcheon, Stephen J. Kaar and Oliver D. Howes; 10. Clozapine Richard Drake; 11. Lithium Allan H. Young and Dilveer S. Sually; 12. Anticonvulsants for mental disorders: valproate, lamotrigine, carbamazepine, and oxcarbazepine Peter S. Talbot; 13. Drugs to treat attention deficit hyperactivity disorder (ADHD) Ulrich Müller-Sedgwick and Jane A. Sedgwick-Müller; 14. Drugs to treat dementia Ross Dunne and Alistair Burns; 15. Drugs to treat substance use disorder (SUD) Julia Sinclair and Lesley Peters; 16. ECT and neuromodulation therapies David Christmas and Keith Matthews; Part III. Specific Therapeutic Areas: 17. Drug treatment in childhood and adolescence David Coghill and Nicoletta Adamo; 18. Drug treatment in later life Simon J. C. Davies; 19. Prescribing in pregnancy and lactation Angelika Wieck and Ian Jones; 20. The clinical management of acute disturbance including rapid tranquilisation Faisil Sethi, Caroline Parker, Aileen O'Brien and Maxine X. Patel; 21. Antipsychotics, weight gain and metabolic risk Stephen J. Cooper and Gavin P. Reynolds; Index.

Reviews

Author Information

Peter M. Haddad is a Senior Consultant Psychiatrist at Hamad Medical Corporation, Doha, Qatar, and Honorary Professor of Psychiatry at the University of Manchester. He is the recipient of several awards including the Morris Markowe Public Education Prize and Gaskell Gold Medal from the Royal College of Psychiatrists. David J. Nutt is a psychiatrist and the Edmund J. Safra Professor of Neuropsychopharmacology and Head of the Centre for Neuropsychopharmacology, Division of Psychiatry, Department of Brain Sciences, Imperial College London. The Times Eureka Science magazine voted him one of the 100 most important figures in British Science, and the only psychiatrist on the list and he was awarded the John Maddox Prize from Nature/Sense about Science.

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions